Real-World Evaluation Of The Visual Performance And Patient Satisfaction With A Novel Full Range Of Vision Toric Intraocular Lens

To report the visual performance and patient-reported outcomes after bilateral implantation of a novel Full Range of Vision toric IOL (enVista™ ENVY) in cataract/refractive lens exchange (RLE) patients with preexisting astigmatism.

This was a retrospective study conducted at one site in Canada.

This study included cataract patients with preexisting corneal astigmatism who underwent cataract surgery/RLE with bilateral implantation of a novel full range of vision toric IOL (enVista Envy toric, Bausch & Lomb). Outcome measures included visual acuities at distance (BCDVA, UCDVA), intermediate (UCIVA) and near (UCNVA) on Early Treatment Diabetic Retinopathy Study (ETDRS) charts, refractive and astigmatic outcomes, and assessment of patient-reported dysphotopsias. Patients were excluded if they had vision-limiting ocular comorbidities.

Twenty-nine eyes (16 toric) of 20 patients were evaluated after a minimum of 28 days. Mean BCDVA was −0.017 logMAR, with 90% of eyes achieving 20/20 or better. Mean UCDVA was 0.041 logMAR with 66% of eyes achieving 20/20 or better, and 86% of eyes achieving 20/25 or better. Mean UCIVA was 0.061 logMAR with 86% of eyes achieving 20/25 or better. UCNVA was 0.060 logMAR with 83% of eyes achieving 20/25 or better. For toric eyes, 100% had ≤0.75D residual cylinder and 88% ≤0.25D. Only one patient reported any of glare, haloes, or starbursts to be more than mildly bothersome (starburst).

At 28 days or more, the enVista™ ENVY and ENVY Toric lenses demonstrated excellent uncorrected visual acuities at distance, intermediate, and near. Eyes implanted with ENVY Toric had consistently low rates of residual cylinder. Patient reported outcomes indicated low rates of bothersome dysphotopsias.